An institutional protocol including socket alveoplasty and primary closure following dental extractions for patients with an elevated risk of developing medication-related osteonecrosis of the jaw.
Humans
Tooth Extraction
/ adverse effects
Female
Bisphosphonate-Associated Osteonecrosis of the Jaw
/ prevention & control
Retrospective Studies
Aged
Middle Aged
Male
Aged, 80 and over
Tooth Socket
/ surgery
Adult
Bone Density Conservation Agents
/ adverse effects
Cone-Beam Computed Tomography
Risk Factors
Zoledronic Acid
/ therapeutic use
Journal
British dental journal
ISSN: 1476-5373
Titre abrégé: Br Dent J
Pays: England
ID NLM: 7513219
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
06
12
2023
accepted:
08
04
2024
revised:
23
03
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
ppublish
Résumé
Background The purpose of this study was to evaluate the outcomes of alveoplasty and primary closure following dental extractions in patients with an elevated medication-related osteonecrosis of the jaw (MRONJ) risk.Study design A retrospective review of 46 patients with an elevated MRONJ risk was conducted. This included a total of 124 teeth extracted, due to unrestorable caries (n = 46; 37%) and peri-apical pathology (n = 44; 35%).Results Our results showed 0% (n = 0) of patients in our cohort developed MRONJ post-operatively. Most patients were being treated with intravenous zoledronic acid for breast cancer (n = 23; 50%), with an average of 15 doses (range 1-72).Conclusions This study supports the use of alveoplasty and primary closure for patients with an elevated MRONJ risk. The authors highlight the importance of pre-operative cone beam computed tomography imaging, optimisation of immune status, post-operative prophylactic antibiotics, and the delay of bone modifying agents recommencement as influential factors in mitigating risk and favouring successful outcomes.
Identifiants
pubmed: 39455783
doi: 10.1038/s41415-024-7968-5
pii: 10.1038/s41415-024-7968-5
doi:
Substances chimiques
Bone Density Conservation Agents
0
Zoledronic Acid
6XC1PAD3KF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-651Informations de copyright
© 2024. The Author(s), under exclusive licence to the British Dental Association.
Références
King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab -a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127: 289-299.
Ruggiero S L, Dodson T B, Aghaloo T, Carlson E R, Ward B B, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws - 2022 Update. J Oral Maxillofac Surg 2022; 80: 920-943.
UK Chemotherapy Board. Medication-related osteonecrosis of the jaw: guidance for the oncology multidisciplinary team. 2019. Available at https://www.rcplondon.ac.uk/file/16661/download (accessed March 2023).
Scottish Dental Clinical Effectiveness Programme. Oral health management of patients at risk of medication-related osteonecrosis of the jaw. 2017. Available at https://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/ (accessed September 2024).
McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018; 24: 527-536.
Ristow O, Rückschloβ T, Schnug G et al. Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake - A Retrospective Cohort Study. Antibiotics 2023; 12: 997.
Coropciuc R, Coopman R, Garip M et al. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - a retrospective study of 240 patients. Bone 2023; 170: 116722.
Patel V, Grossman S, Wali R et al. The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 1: an overview. Br Dent J 2022; DOI: 10.1038/s41415-021-3825-y.
Patel V, Wali R, Burns M et al. The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer. Br Dent J 2022; 232: 95-100.
Patel V, Burns M, Patel S et al. The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 3: prostate cancer. Br Dent J 2022; DOI: 10.1038/s41415-022-3928-0.
Patel V, Patel S, Grossman S et al. The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 4: miscellaneous cancers. Br Dent J 2022; 232: 213-218.
Fernandes U, Guidi G, Martins D et al. Breast cancer in young women: a rising threat: a 5-year follow-up comparative study. Porto Biomed J 2023; 8: e213.
Liu C, Xiong Y-T, Zhu T, Liu W, Tang W, Zeng W. Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: An Evidence Mapping Review and Meta-Analysis. J Clin Med 2022; 12: 239.
Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review. Heliyon 2020; 6: e03795.
Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, Bollero P. The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ). Biomed Res Int 2021; 2021: 4948139.
Nowak S M, Sacco R, Mitchell F L, Patel V, Gurzawska-Comis K. The effectiveness of autologous platelet concentrates in prevention and treatment of medication-related osteonecrosis of the jaws: a systematic review. J Craniomaxillofac Surg 2024; 52: 672-691.
Vescovi P, Giovannacci I, Merigo E et al. Tooth extractions in high-risk patients under bisphosphonate therapy and previously affected with osteonecrosis of the jaws: surgical protocol supported by low-level laser therapy. J Craniofac Surg 2015; 26: 696-699.
Schiodt M. When and How to Extract Teeth under Antiresorptive Treatment - Guidelines for the Dental Practitioner in Denmark. In Proceedings of the 3rd International Symposium on Medication Related Osteonecrosis of the Jaw (MRONJ). Denmark, 15 November 2019.
Mauceri R, Coniglio R, Abbinante A et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer 2022; 30: 6429-6440.
AWMF Online. S3 guideline on antiresorptive-associated osteonecrosis of the jaw (AR-ONJ). 2018. Available at www.awmf.org (accessed May 2023).
Schwech N, Nilsson J, Gabre P. Incidence and risk factors for medication-related osteonecrosis after tooth extraction in cancer patients - a systematic review. Clin Exp Dent Res 2023; 9: 55-65.
Cabras M, Gambino A, Broccoletti R, Sciascia S, Arduino P G. Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. J Oral Sci 2021; 63: 217-226.
Ferlito S, Puzzo S, Liardo C. Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 2011; 69: 1-4.
Kyrgidis A, Vahtsevanos K, Koloutsos G et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26: 4634-4638.
Otto S, Aljohani S, Fliefel R et al. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ). Medicina 2021; 57: 463.
Spanou A, Nelson K, Ermer M A, Steybe D, Poxleitner P, Voss P J. Primary wound closure and perioperative antibiotic therapy for prevention of bisphosphonate-related osteonecrosis of the jaw after tooth extraction. Quintessence Int 2020; 51: 220-228.
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018; 69: 177-187.
Abtahi J, Agholme F, Aspenberg P. Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. Int J Oral Maxillofac Surg 2013; 42: 632-636.
Ristow O, Rückschloβ T, Moratin J et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake - a randomized pilot trial. Oral Dis 2021; 27: 532-546.
Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 2010; 68: 107-110.
Otto S, Tröltzsch M, Jambrovic V et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 2015; 43: 847-854.
Soutome S, Otsuru M, Murata M et al. Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study. Support Care Cancer 2022; 30: 7241-7248.
Sedghizadeh P P, Kumar S K, Gorur A, Schaudinn C, Shuler C F, Costerton J W. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009; 140: 1259-1265.
Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss P J. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig 2017; 21: 127-134.
Gaêta-Araujo H, Ferreira Leite A, de Faria Vasconcelos K et al. Why do some extraction sites develop medication-related osteonecrosis of the jaw and others do not? A within-patient study assessing radiographic predictors. Int J Oral Implantol 2021; 14: 87-98.
Nicolatou-Galitis O, Papadopoulou E, Vardas E et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents Oral Dis 2020; 26: 955-966.
Saia G, Blandamura S, Bettini G et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 2010; 68: 797-804.
Bedogni A, Blandamura S, Lokmic Z et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 358-364.
Shimamoto H, Grogan T R, Tsujimoto T et al. Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws? Dentomaxillofac Radiol 2018; 47: 20170290.
Al-Sarraj M, Burns M, Patel V. Pre-existing medication related osteonecrosis of the jaw before dental extraction. Br Dent J 2023; 235: 783-788.
Moreno-Rabié C, Lapauw L, Gaêta-Araujo H et al. Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction. Sci Rep 2022; 12: 11280.
King R, Zebic L, Patel V. Deciphering novel chemotherapy and its impact on dentistry. Br Dent J 2020; 228: 415-421.
Zebic L, Patel V. Preventing medication-related osteonecrosis of the jaw. BMJ 2019; 365: 1733.
Poxleitner P, Ermer M A, Trittler R et al. Concentration of Penicillin G in Jawbone Affected by Antiresorptive Agent-Related Osteonecrosis following a Single Preoperative Dose. Antibiotics 2020; 10: 17.
Montefusco V, Gay F, Spina F et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49: 2156-2162.
Colella A, Yu E, Sambrook P, Hughes T, Goss A. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis? J Oral Maxillofac Surg 2023; 81: 232-237.
Otto S, Abu-Id M H, Fedele S et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence - a multi-centre study. J Craniomaxillofac Surg 2011; 39: 272-277.
Ng T L, Tu M M, Ibrahim M F K et al. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer 2021; 29: 925-943.
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 2016; 6: 97-104.
Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: a literature review. J Oral Biosci 2019; 61: 99-104.
Ruggiero S L, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-441.
Patel V, Mansi J, Ghosh S et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 2018; 224: 74-79.